Literature DB >> 1312902

Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture.

A Tanizawa1, Y Pommier.   

Abstract

Camptothecin-resistant DC3F Chinese hamster lung fibroblast cell lines were obtained after mutagenic treatment with ethylmethanesulfonate and subsequent exposure to 1 microM camptothecin (CPT). The most resistant cell line, which was obtained after exposure to CPT for 10 days, was designated DC3F/C-10. Comparison of 50% inhibitory concentration values after 8-h CPT treatments showed that DC3F/C-10 cells were 134-fold resistant to CPT. Resistance was associated with marked reduction of CPT-induced DNA single-strand breaks and DNA-protein cross-links. This reduction was not due to reduced amounts of immunoreactive DNA topoisomerase I protein, although nuclear extracts from DC3F/C-10 cells had less enzyme catalytic activity than those from DC3F cells. Also, fast protein liquid chromatography-purified DNA topoisomerase I from DC3F/C-10 had lower specific catalytic activity than that from DC3F cells. DNA topoisomerase I from DC3F/C-10 was resistant to inhibition of catalytic activity and induction of DNA cleavage by CPT. These results suggest that CPT resistance in DC3F/C-10 cells is due to qualitative alteration of DNA topoisomerase I.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312902

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Targeted disruption of the mouse topoisomerase I gene by camptothecin selection.

Authors:  S G Morham; K D Kluckman; N Voulomanos; O Smithies
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

Review 2.  The challenge of drug resistance in cancer treatment: a current overview.

Authors:  Michail Nikolaou; Athanasia Pavlopoulou; Alexandros G Georgakilas; Efthymios Kyrodimos
Journal:  Clin Exp Metastasis       Date:  2018-05-24       Impact factor: 5.150

Review 3.  Topoisomerase I in multiple drug resistance.

Authors:  A Pessina
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin.

Authors:  A Tanizawa; K W Kohn; Y Pommier
Journal:  Nucleic Acids Res       Date:  1993-11-11       Impact factor: 16.971

5.  A novel mutation in DNA topoisomerase I of yeast causes DNA damage and RAD9-dependent cell cycle arrest.

Authors:  N A Levin; M A Bjornsti; G R Fink
Journal:  Genetics       Date:  1993-04       Impact factor: 4.562

6.  Topoisomerase I inhibitors and drug resistance.

Authors:  R E Parchment; A Pessina
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

Review 7.  Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.

Authors:  C J Gerrits; M J de Jonge; J H Schellens; G Stoter; J Verweij
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.

Authors:  P B Jensen; B Holm; M Sorensen; I J Christensen; M Sehested
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts.

Authors:  G Pratesi; M Tortoreto; C Corti; R Giardini; F Zunino
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

10.  Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.

Authors:  M Sorensen; M Sehested; P B Jensen
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.